Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma

Transfusion

Volumn 50, Issue 4, 2010, Pages 926-931

  Smith, James ^a,b   Rock, Gail ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Oklahoma Blood Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTICOAGULANT PROTEIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; FRESH FROZEN PLASMA; PLASMINOGEN; PROTEIN S; PROTHROMBIN; RIBOFLAVIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

APHERESIS; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; MIRASOL PATHOGEN REDUCTION TECHNOLOGY SYSTEM; PROTEIN QUALITY; TECHNOLOGY; ULTRAVIOLET RADIATION;

BLOOD COAGULATION FACTORS; BLOOD COMPONENT REMOVAL; BLOOD DONORS; BLOOD PRESERVATION; BLOOD PROTEINS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; HUMANS; METHYLENE BLUE; PATIENT SELECTION; PLASMA; RIBOFLAVIN; SOLVENTS; ULTRAVIOLET RAYS;

EID: 77950239200     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02517.x     Document Type: Article

References (42)

1. Grant IH, Gold JW, Wittner M, Tanowitz HB, Nathan C, Mayer K, Reich L, Wollner N, Steinherz L, Ghavimi F, O'Reilly RJ, Armstrong D. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med 1989 111 : 849 51.
2. Leiby DA, Lenes BA, Tibbals MA, Tames-Olmedo MT. Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. New Engl J Med 1999 341 : 1237 9.
3. Wu CG, Mason B, Jong J Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MY. Parvovirus B19 transmission by a high-purity Factor VIII concentrate. Transfusion 2005 45 : 1003 10.
4. Cangelosi JJ, Sarria JC, Herwaldt BL, Indrikovs AJ. Transmission of Babesia microti by blood transfusion in Texas. Vox Sang 2008 95 : 331 4.
5. Marques A, Torres S, Davis JM. The current infectious risks of transfusions. Surg Infect 2005 6 : S23 31.
6. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hem 2004 11 : 346 50.
7. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003 43 : 1322 39.
8. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004 33 : 1 7.
9. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, Metzel P, Corash L. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004 44 : 1496 504.
10. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005 45 : 580 90.
11. Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006 90 : 85 91.
12. Fast LD, DiLeone G, Li J, Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006 46 : 642 8.
13. Rentas F, Harman R, Gomez C, Salata J, Childs J, Silva T, Lippert L, Montgomery J, Richards A, Chan C, Jiang J, Reddy H, Li J, Goodrich R. Inactivation of Orientia tsutsugamushi in red blood cells, plasma and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007 47 : 240 7.
14. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard L, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004 44 : 877 85.
15. Zempleni J, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 1996 63 : 54 66.
16. Unna K, Greslin JG. Studies on the toxicity and pharmacology of riboflavin. J Pharmacol 1942 76 : 75 80.
17. Leclerc J. Influence of thiamine, riboflavin and vitamin B6 content in food on tissue content of these vitamins in the female lactating rat and young rats. Ann Nutr Aliment 1974 28 : 11 20.
18. Kumar V, Lockerbie O, Keil SD, Ruane P, Platz M, Martin C. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004 80 : 15 21.
19. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006 35 : 5 17.
20. Ruggeri ZM, Zimmerman TS. The complex multimeric structure composition of factor VIII/von Willebrand factor. Blood 1981 57 : 1140 3.
21. Snider CE, Moore JC, Warkentin TE, Finch CN, Hayward CP, Kelton JG. Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thombotic thrombocytopenic purpura. Am J Hematol 2004 77 : 387 90.
22. Tsai H, Chandler W, Sarode R, Hoffman R, Jelacic S, Habeeb RL, Watkins SL, Wong CS, Williams GD, Tarr PI. Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in escherichia coli 0157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001 49 : 5.
23. Wieding JU, Hellstern P, Köhler M. Inactivation of viruses in fresh-frozen plasma. Ann Hemat 1993 67 : 259 66.
24. Doyle S, O'Brien P, Murphy K, Fleming C, O'Donnell J. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 2003 14 : 283 7.
25. Cardigan R, Philpot K., Cookson P, Luddington R. Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate. Transfusion 2009 49 : 696 703.
26. Zeiler T, Riess H, Wittmann G, Zlimmermann R, Muller C, Heuft HG, Huhn D. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 1994 34 : 685 9.
27. Depasse F, Sensebe L, Seghatchian J, Andreu G, Samama MM. The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerization indices. Trans Apher Sci 2005 33 : 63 9.
28. Suotaka AM, Blomback M, Chapman J. Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion 2003 43 : 568 75.
29. De Valensart N, Rapaille A, Goossenaerts E, Irsch J, Lin L, Deneys V. Analysis of the impact of INTERCEPT treatment on fresh plasma: preservation of coagulation factors and inhibitors functional activity. Vox Sang 2008 95 Suppl 1 : 31.
30. Alvarez-Larrán A, Del Rio J, Ramirez C, Albo C, Peña F, Campos A, Cid J, Muncunill J, Sastre JL, Sanz C, Pereira A. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004 86 : 246 51.
31. Goodrich L, Ghielli M, Hansen E, Woolum M, Gampp D, Goodrich R, Keil S. Riboflavin and UV light inactivate enveloped and non-enveloped viruses in platelet concentrates under conditions which maintain cell quality. Vox Sang 2002 83 : 111.
32. Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich R. Pathogen inactivation of Trypanosome cruzi in plasma and platelets concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007 37 : 131 7.
33. Hornsey VS, Drummond O, Morrison A, McMillan L, MacGregor IR, Prowse CV. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulant proteins. Transfusion. 2009 49 : 2167 72.
34. Crettaz D, L Sendebe L, Vu DH, Schneider P, Depasse F, Bienvenut WV, Quadroni M, Tissot JD. Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter. Proteomics 2004 4 : 881 91.
35. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005 106 : 11 7.
36. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Trans Med 2004 14 : 39 44.
37. Bihm DJ, Ettinger A, Buyaert-Hoefen KA, Hendrix BK, Maldonado-Codina G, Rock G, Giclas PC, Goodrich RP. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during two years of storage at -30°C. Vox Sang In press 2009.
38. Francini M, Capra F, Targher G, Montagnana M, Lippi G. Relathionship between ABO group and von Willebrand factor levels: from biology to clinical implications. Thromb J 2007 5 : 14 8.
39. Moake J, Chintagumpala M, Turner N, McPherson P, Nolasco L, Steuber C, Santiago-Borrero P, Horowitz M, Pehta J. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994 84 : 490 7.
40. Aznar JA, Bonanad S, Montoro JM, Hurtado C, Cid AR, Soler MA, De Miguel A. Influence of Methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitate and cryosupernatants. Vox Sang 2000 7 : 156 60.
41. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006 46 : 1693 704.
42. Evans G, Llewelyn C, Luddington R, Baglin TP, Williamson LM. Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haem 1999 21 : 119 23.